Development
Ultralife Corporation
ULBI
$7.70
-$0.155-1.98%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 150.20M | 143.95M | 133.38M | 131.84M | 119.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.20M | 143.95M | 133.38M | 131.84M | 119.50M |
| Cost of Revenue | 114.32M | 111.13M | 103.51M | 102.44M | 92.77M |
| Gross Profit | 35.88M | 32.82M | 29.88M | 29.40M | 26.73M |
| SG&A Expenses | 21.72M | 21.36M | 21.39M | 21.41M | 20.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.38M | 139.85M | 132.15M | 130.93M | 120.34M |
| Operating Income | 6.82M | 4.10M | 1.23M | 908.00K | -842.00K |
| Income Before Tax | 5.62M | 3.54M | -502.00K | -446.00K | -1.41M |
| Income Tax Expenses | 1.53M | 997.00K | -208.00K | -326.00K | -382.00K |
| Earnings from Continuing Operations | 4.09 | 2.55 | -0.29 | -0.12 | -1.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.00K | -15.00K | -3.00K | 1.00K | -3.00K |
| Net Income | 4.10M | 2.53M | -297.00K | -119.00K | -1.03M |
| EBIT | 6.82M | 4.10M | 1.23M | 908.00K | -842.00K |
| EBITDA | 10.81M | 8.23M | 5.52M | 5.37M | 3.50M |
| EPS Basic | 0.25 | 0.16 | -0.02 | -0.01 | -0.06 |
| Normalized Basic EPS | 0.25 | 0.17 | 0.01 | 0.01 | -0.04 |
| EPS Diluted | 0.25 | 0.15 | -0.03 | -0.02 | -0.07 |
| Normalized Diluted EPS | 0.25 | 0.17 | 0.01 | 0.01 | -0.04 |
| Average Basic Shares Outstanding | 64.65M | 64.54M | 64.53M | 64.50M | 64.45M |
| Average Diluted Shares Outstanding | 64.72M | 64.55M | 64.55M | 64.52M | 64.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |